It would be interesting to see the actual data from this trial and how it compares to the 130 week NTCELL results based on the UPDRS motor function measure.
A couple of quotes that stand out from articles I've read regarding this study "It is worth noting that these effects were subtle - they didn't perform better on cognitive tests, and there wasn't a visible improvement in their day-to-day symptoms"...."Parkinson's progresses slowly and the difference in this 60-week trial was definitely there, but was 'trivial' in terms of the impact on day-to-day life, say the researchers".
Although NTCELL has also not yet proven it is able to halt the progress of Parkinson's when the element of bias is removed during double blinded trial we will all know very shortly....
LCT Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
